Drug Profile
Elebsiran - Alnylam Pharmaceuticals
Alternative Names: ALN-HBV02; BRII-835; VIR-2218Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Brii Biosciences; Vir Biotechnology
- Class Antivirals; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference; Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 05 Mar 2024 Vir Biotechnology completes enrollment in the phase II SOLSTICE trial in Hepatitis D (Monotherapy, Combination therapy) in New Zealand, Bulgaria, Germany, Italy, Moldova, Romania, the United Kingdom, Netherlands (SC, Injection) (NCT05461170) (EudraCT2022-001993-78)
- 14 Nov 2023 Pharmacokinetics data from a pooled analysis of phase Ib/II and phase II trials in Hepatitis B released by Brii Biosciences
- 14 Nov 2023 Updated efficacy and adverse events data from a phase II trial in Hepatitis B released by Brii Biosciences